Serum Tumor Markers at Exocrine Adenocarcinoma of Pancreas
Holubec L., Fínek J., 1Topolčan O., 2Svobodová Š.
Onkologické a radioterapeutické oddělení FN, Plzeň 1ONM – úsek imunodiagnostiky FN, Plzeň 2III. interní klinika 1. LF UK a VFN, Praha
Pancreatic cancer represents a group of cancers with the worst prognosis. There exists only one method of successful
therapy - radical surgery, i.e. the complete resection of the tumor. However, only 5 % of cases are diagnosed in
the early stage. More than 60 % are recognised in the period of advanced disease. For those patients only palliative
treatment can be used. Only early diagnosis can ensure better therapy results. Possibility of early diagnosis based on
imaging and endoscope methods is at present very limited due to the anatomical location of pancreas. Serum tumor
markers assessment might represent one of the possibilities of early detection of the pancreatic cancer. Review summarizes
current knowledge on the use of tumor markers for diagnosis, prognosis and therapy monitoring of pancreatic
exocrine adenocarcinomas with respect to the clinical use at the daily routine practice.
pancreatic adenocarcinoma, tumor markers, CA 19-9.